![Jean-Pierre Garnier](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Jean-Pierre Garnier
Vorsitzender bei CELLECTIS S.A.
Vermögen: 993 877 $ am 30.11.2025
Profil
Jean-Pierre Garnier ist ein französischer Geschäftsmann, der an der Spitze von 14 verschiedenen Unternehmen stand und derzeit die Position des Non-Executive Chairman von Cellectis SA und des Chairman für Carmat SA innehat. Dr. Garnier ist außerdem Mitglied des Vorstands von Radius Health, Inc. und des Max-Planck-Instituts für biophysikalische Chemie sowie von Carrier Global Corp. und Operating Partner bei Advent International LLC. Zuvor war er Chairman bei NormOxys, Inc. und Chairman bei Alzheon, Inc. sowie Chairman von ABIONYX Pharma SA und Chairman von Cerenis Therapeutics, Inc. (eine Tochtergesellschaft von ABIONYX Pharma SA), Chairman von Idorsia Ltd., Chairman von Idorsia Pharmaceuticals Ltd., Chief Executive Officer von GlaxoSmithKline Plc und Chief Executive Officer von Smithkline Beecham Plc (eine Tochtergesellschaft von GlaxoSmithKline Plc), President von e.Nvizion Communications Group Ltd., Director von Actelion Ltd., Chief Executive Officer von Pierre Fabre SA, President von Schering-Plough Corp. und Advisor von Quaker Partners Management LP. Dr. Garnier erwarb einen MBA an der Stanford University sowie einen Doktortitel und einen Hochschulabschluss an der Louis Pasteur University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 09.04.2025 | 18.110 ( 0 % ) | 993 877 $ | 30.11.2025 | |
CELLECTIS S.A. -.--% | 15.02.2025 | 0 ( -.--% ) | - $ | 30.11.2025 |
BIOAGE LABS, INC. -.--% | 05.06.2025 | 0 ( -.--% ) | - $ | 30.11.2025 |
Aktuelle Nachrichten zu Jean-Pierre Garnier
Aktive Positionen von Jean-Pierre Garnier
| Unternehmen | Position | Beginn |
|---|---|---|
| CARRIER GLOBAL CORPORATION | Direktor/Vorstandsmitglied | 03.04.2020 |
| CELLECTIS S.A. | Vorsitzender | 05.11.2020 |
| BIOAGE LABS, INC. | Vorsitzender | 20.08.2024 |
Carrier Corp.
 Carrier Corp. Industrial MachineryProducer Manufacturing Manufactures air conditioning, heating & refrigeration equipment | Direktor/Vorstandsmitglied | - |
Advent International LLC
 Advent International LLC Investment ManagersFinance Provides risk capital and investments | Corporate Officer/Principal | - |
Ehemalige bekannte Positionen von Jean-Pierre Garnier
| Unternehmen | Position | Ende |
|---|---|---|
| CARMAT | Vorsitzender | 22.12.2022 |
| RADIUS HEALTH, INC. | Direktor/Vorstandsmitglied | 15.08.2022 |
Idorsia Pharmaceuticals Ltd.
 Idorsia Pharmaceuticals Ltd. Develops and commercializes pharmaceuticals | Vorsitzender | 13.05.2020 |
| IDORSIA LTD | Vorsitzender | 13.05.2020 |
| ░░░░░░ ░░░░░░░░░░░░ ░░░░░ | ░░░░░░░░░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Ausbildung von Jean-Pierre Garnier
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 29 |
|---|---|
Schering-Plough Corp.
 Schering-Plough Corp. Manufactures and sells pharmaceutical & health care products | |
United Technologies Corp.
 United Technologies Corp. Manufactures engine parts, elevators, and air-conditioning equipment | |
Smithkline Beecham Plc
 Smithkline Beecham Plc Pharmaceuticals: OtherHealth Technology Develops and manufactures pharmaceutical products | Health Technology |
e.Nvizion Communications Group Ltd.
 e.Nvizion Communications Group Ltd. Financial ConglomeratesFinance Development stage company | Finance |
Radius Health, Inc.
 Radius Health, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company that develops and commercializes endocrine therapeutics | Health Technology |
Advent International LLC
Advent International LLC Investment ManagersFinance Provides risk capital and investments | Finance |
NormOxys, Inc.
 NormOxys, Inc. Pharmaceuticals: MajorHealth Technology Develops small-molecule therapeutics for the treatment of cancer | Health Technology |
Newman's Own Foundation
 Newman's Own Foundation Operates as a charity | |
Alzheon, Inc.
 Alzheon, Inc. Develops treatment for brain health, memory and aging | |
GSK Plc
 GSK Plc Pharmaceuticals: MajorHealth Technology Develops, manufactures and distributes vaccines and other pharmaceutical products | Health Technology |
Stanford University
 Stanford University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Renault SA
 Renault SA Motor VehiclesConsumer Durables Manufactures and distributes automobiles and other motor vehicles | Consumer Durables |
Carrier Corp.
Carrier Corp. Industrial MachineryProducer Manufacturing Manufactures air conditioning, heating & refrigeration equipment | Producer Manufacturing |
Actelion Ltd.
 Actelion Ltd. Pharmaceuticals: MajorHealth Technology Develops, produces and markets pharmaceutical drugs | Health Technology |
Pierre Fabre SA
 Pierre Fabre SA BiotechnologyHealth Technology Engages in research and preclinical development of biologics & pharmaceuticals | Health Technology |
Pierre Fabre Participations SAS
 Pierre Fabre Participations SAS Pharmaceuticals: MajorHealth Technology Manufactures and distributes dermatology and cosmetic products | Health Technology |
Quaker Partners Management LP
 Quaker Partners Management LP Investment ManagersFinance Quaker Partners Management invests in healthcare companies located in the United States primarily in East Coast. The firm targets companies operating in the fields of biopharmaceuticals, medical devices, human diagnostics, specialty pharmaceuticals and healthcare services. It participates in seed and early stage capital requirements. | Finance |
Cellectis SA
 Cellectis SA Pharmaceuticals: MajorHealth Technology Engages in the upstream research of genome engineering and in the development of pre-engineered products for pharmaceutical industry, cell therapies, seed companies, and laboratory researchers | Health Technology |
ABIONYX Pharma SA
 ABIONYX Pharma SA Pharmaceuticals: MajorHealth Technology Discovers, develops and commercializes novel HDL therapies for the treatment of cardiovascular and metabolic diseases | Health Technology |
Cerenis Therapeutics, Inc.
 Cerenis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Discovers, develops and commercializes drugs | Health Technology |
Carmat SA
 Carmat SA Medical SpecialtiesHealth Technology Specializes in the construction of artificial hearts | Health Technology |
Weill Cornell Medical College
 Weill Cornell Medical College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Max Planck Institute For Biophysical Chemistry
 Max Planck Institute For Biophysical Chemistry Functions as a College/University | |
Max Planck Florida Institute for Neuroscience
 Max Planck Florida Institute for Neuroscience Researches and develops on neuroscience | |
BioAge Labs, Inc.
 BioAge Labs, Inc. Develops therapies obesity for metabolic diseases | |
Idorsia Ltd.
 Idorsia Ltd. Engages in the discovery, development and commercialization of medicines for unmet medical needs | |
Idorsia Pharmaceuticals Ltd.
Idorsia Pharmaceuticals Ltd. Develops and commercializes pharmaceuticals | |
Carrier Global Corp.
 Carrier Global Corp. Manufactures, sells and installs HVAC, refrigeration, fire and security solutions | |
Louis Pasteur University
 Louis Pasteur University Functions as a College/University |
